This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Nature Reviews Cardiology, Published online: 03 February 2025; doi:10.1038/s41569-025-01132-3 In this Clinical Outlook, we describe available multiomic studies in cardiovascular medicine, discuss the advantages and potential of multiomic techniques for clinical translation in cardiology, and highlight three promising aspects: the generation of unprecedented (..)
tim.hodson Tue, 03/25/2025 - 16:19 March 25, 2025 Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive clinical trial program at the American College of Cardiology (ACC) 74 th Annual Scientific Session & Expo 2025 , in Chicago, IL, March 29-31, 2025. Bayer Pharmaceuticals.
Nature Reviews Cardiology, Published online: 02 January 2025; doi:10.1038/s41569-024-01110-1 In this Review, Dey and colleagues explore the pathobiology of coronary atherosclerotic plaques and perivascular adipose tissue, describe their phenotyping with computed tomography coronary angiography, and discuss potential future applications in clinical (..)
Diagnosis may be challenging given diverse symptomatology, absence of classical symptoms on presentation, and difficulties in the interpretation of biomarkers. Acute coronary syndromes (ACS) are common in patients with end-stage renal disease (ESRD).
tim.hodson Mon, 02/03/2025 - 12:30 January 29, 2025 Roche announced today that the Tina-quant Lipoprotein (a) Gen.2 2 Molarity assay has received 510(k) clearance from the United States Food and Drug Administration (FDA). This will be the first 510(k) cleared test of its kind available in the U.S.
Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025. Urinary albumin-to-creatinine ratio is an attractive, unifying biomarker of cardiovascular, kidney, and metabolic conditions that may be useful for identifying and monitoring disease trajectory.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP101-AWMP101, February 1, 2025. It remains unclear if the biomarkers used in the trial reliably identified atrial cardiopathy. It remains unclear if the biomarkers used in the trial reliably identified atrial cardiopathy. and Canada.
Stroke, Volume 56, Issue Suppl_1 , Page ATP140-ATP140, February 1, 2025. Conclusion:We identify potential biomarkers and therapeutic targets and offer an opportunity for more precise prognosis and treatment in ischemic stroke. AUC range:0.65-0.99).Conclusion:We
Stroke, Volume 56, Issue Suppl_1 , Page ATMP1-ATMP1, February 1, 2025. Studies have searched for biomarkers for CA to provide early and easy diagnosis of unruptured CA through blood transcriptome analysis; however, biomarkers from individual studies cannot be validated across studies due to sample size.
Stroke, Volume 56, Issue Suppl_1 , Page ATP44-ATP44, February 1, 2025. However, no effective serum biomarker has been established for early diagnosis or prediction of the disease progression. However, no effective serum biomarker has been established for early diagnosis or prediction of the disease progression.
Stroke, Volume 56, Issue Suppl_1 , Page AWP230-AWP230, February 1, 2025. Hemorrhagic strokes (HS) are increasingly significant causes of disability and mortality worldwide, making the use of blood biomarkers for their diagnosis and prognosis critical.
Stroke, Volume 56, Issue Suppl_1 , Page ATP49-ATP49, February 1, 2025. Analysis of extracellular vesicles (EVs), important constituents of the intercellular communication pathway, may offer new ways to evaluate pathological processes of sCVD as well as serve as novel biomarkers or identify new avenues for therapy. years of education.
Stroke, Volume 56, Issue Suppl_1 , Page AWP396-AWP396, February 1, 2025. This study seeks to expand the current understanding of pial collateral plasticity by correlating cerebrovascular biomarker levels of Soluble Tie2, Angiopoietin-1 (Ang1), Angiopoietin-2 (Ang2) to collateral function in human patients with acute ischemic stroke.
Stroke, Volume 56, Issue Suppl_1 , Page AWP227-AWP227, February 1, 2025. Early intervention has been shown to improve patient prognosis, highlighting the necessity of sensitive biomarkers. These biomarkers could facilitate timely interventions, potentially improving outcomes for stroke patients.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP32-AWMP32, February 1, 2025. We conducted internal validation on the same samples using the PeptiQuant Plus biomarker assessment kits (BAK-270) for targeted protein quantitation (Figure 1).Results:We Results:We included 100 patients (mean age 58.6
Stroke, Volume 56, Issue Suppl_1 , Page A33-A33, February 1, 2025. Introduction:Net water uptake (NWU) is a novel biomarker which measures edema and tissue injury from the degree of hypoattenuation on non-contrast CT and may serve as a precision tool for predicting outcomes after acute ischemic stroke (AIS).
Stroke, Volume 56, Issue Suppl_1 , Page AWP88-AWP88, February 1, 2025. 4.94), but not with 90-day mRS or mortality.Conclusion:Serum creatinine-based biomarkers of renal dysfunction were associated with faster progressor phenotype of ACLVO stroke, higher mRS, and mortality at 90 days. mg/dL, p < 0.05) and lower median eGFR (66.2
Stroke, Volume 56, Issue Suppl_1 , Page A146-A146, February 1, 2025. Conclusions:Our discovery proteomics study highlights the potential of DIA-MS proteomics as a valuable tool for discovering novel protein biomarkers to distinguish TIA from MIM. These findings warrant validation in larger, longitudinal studies.
Stroke, Volume 56, Issue Suppl_1 , Page AWP35-AWP35, February 1, 2025. Finally, as neutrophil counts (and the ratio of neutrophils to lymphocytes) are reported to be a biomarker for DCI, we assessed these measures too. Neutrophils are reported to be critical mediators of to poor outcome after subarachnoid hemorrhage (SAH). nucleosome.
tim.hodson Tue, 03/25/2025 - 16:19 March 25, 2025 Bayer plans to present data from 13 new analyses from across t he KERENDIA (finerenone) comprehensive clinical trial program at the American College of Cardiology (ACC) 74 th Annual Scientific Session & Expo 2025 , in Chicago, IL, March 29-31, 2025. Bayer Pharmaceuticals.
Stroke, Volume 56, Issue Suppl_1 , Page ATP377-ATP377, February 1, 2025. Timely and accurate risk stratification of IAs is paramount.Objective:Aneurysm wall enhancement (AWE) is a potential imaging biomarker for risk stratification.
Stroke, Volume 56, Issue Suppl_1 , Page AWP359-AWP359, February 1, 2025. Background:Mechanical thrombectomy has been associated with improved outcomes in patients with acute ischemic stroke. However, not all patients with successful reperfusion experience good functional outcomes.
Stroke, Volume 56, Issue Suppl_1 , Page A74-A74, February 1, 2025. There is a need for surrogate imaging biomarkers that more strongly associate with functional outcome, to refine prognostication and facilitate development of EVT-adjuvant neuroprotective therapies.
Publication date: Available online 6 January 2025 Source: The American Journal of Cardiology Author(s): Srikanth Adusumalli, Cian P. McCarthy, Craig A. Magaret, Rhonda F. Rhyne, Farouc A. Jaffer, James L.
Stroke, Volume 56, Issue Suppl_1 , Page ATP341-ATP341, February 1, 2025. Introduction:Peripheral blood-based biomarker development for neurological diseases such as ischemic stroke has traditionally focused on measuring alterations in leukocyte number and composition.
Stroke, Volume 56, Issue Suppl_1 , Page ATP209-ATP209, February 1, 2025. This workflow, which involves downloading imaging data from a clinical trials electronic data capture (EDC) system, performing biomarker analyses, and then re-entering data into the EDC, can be cumbersome when performed manually.
Stroke, Volume 56, Issue Suppl_1 , Page AWP338-AWP338, February 1, 2025. Furthermore, these patients could benefit from early surgical intervention if these biomarkers were to be detected. Introduction:Extracranial carotid artery pathology accounts for 15-20% of ischemic strokes.
Stroke, Volume 56, Issue Suppl_1 , Page AWP6-AWP6, February 1, 2025. Background and Purpose:Whether imaging markers of cerebral small vessel disease on computed tomography (CT-CSVD) relates to early clinical outcomes after intravenous thrombolysis for acute ischemic stroke remains not well understood.
Stroke, Volume 56, Issue Suppl_1 , Page AWP226-AWP226, February 1, 2025. Specific biomarkers of platelet activity would improve our understanding of HE and could point towards targeted treatments. Objective:Hematoma expansion (HE) predicts disability and death after intracerebral hemorrhage (ICH).
Marea still has to prove MAR001’s performance, although in its Phase 1 trial MAR001 significantly lowered remnant cholesterol levels and improved metabolic biomarkers. Results from its current Phase 1b/2a trial is due to be completed by the end of 2024, and its Phase 2b trial is scheduled to start in early 2025.
Stroke, Volume 56, Issue Suppl_1 , Page AWP224-AWP224, February 1, 2025. Background:The astroglial protein GFAP (glial fibrillary acidic protein) is a promising biomarker candidate for prehospital differentiation between intracerebral hemorrhage (ICH) and ischemic stroke. All blood samples were collected in the prehospital phase.
Stroke, Volume 56, Issue Suppl_1 , Page AWP370-AWP370, February 1, 2025. Previous studies have identified numerous biomarkers, such as coagulation and platelet factors, which may predict patients at-risk for DCI, but to-date, no markers are widely utilized in the clinical setting.
Stroke, Volume 56, Issue Suppl_1 , Page AWP318-AWP318, February 1, 2025. Conclusions:In a multicenter prospective cohort of patients with cryptogenic stroke, history of cancer was not independently associated with selected biomarkers for atrial cardiopathy. to 0.03), PTFV1(beta-coefficient, -0.04; 95% CI, -0.10
Stroke, Volume 56, Issue Suppl_1 , Page AWP232-AWP232, February 1, 2025. Conclusion:Spot sign visualized in conventional vascular imaging is a highly specific radiological biomarker for predicting mortality and poor functional outcomes in patients with ICH. For poor functional outcomes, OR was 4.13 (95% CI: 3.15-5.42;I2=33%).Conclusion:Spot
Stroke, Volume 56, Issue Suppl_1 , Page AWMP97-AWMP97, February 1, 2025. At baseline, DTI-ALPS was significantly correlated with PSQI (r = -0.174, p = 0.005) and various imaging biomarkers of CSVD after adjusting for age, gender, vascular risk factors, and ApoE4.
Stroke, Volume 56, Issue Suppl_1 , Page ATP320-ATP320, February 1, 2025. Future studies with larger sample sizes are needed to determine whether these biomarkers can be utilized for the identification, diagnosis, and management of stroke.Keywords:Kynurenine; stroke; tryptophan; kynurenic acid; biomarkers.
Stroke, Volume 56, Issue Suppl_1 , Page ADP16-ADP16, February 1, 2025. Conclusions:Our study revealed distinct panels of protein biomarkers capable of classifying AIS patients into NIHSS-defined severity subgroups with high accuracy, particularly for mild, severe, and critical categories. to classify mild NIHSS, 0.66
Attendees dove into cutting-edge topics, including FDA updates, resistant hypertension, and cardiac biomarkers. “I Looking Ahead: The Future of Cardiorenal Metabolic Medicine For those unable to attend, on-demand access to the 19th Annual CMHC content will be available from December 2024 to December 2025. Learn more now!
Stroke, Volume 56, Issue Suppl_1 , Page AWMP16-AWMP16, February 1, 2025. The quantified biomarker of this pattern can be used to monitor the decline in cognitive function. Pseudocontinuous arterial spin labeling imaging was used to identify hypoperfused regions (HypoR) in the discovery cohort.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP4-ATMP4, February 1, 2025. This study aims to identify serum protein biomarkers specifically targeting cerebral edema in EBI and cell-specific interventional targets.Methods:This study is based on a prospective observational cohort at a single tertiary referral center.
Stroke, Volume 56, Issue Suppl_1 , Page ADP54-ADP54, February 1, 2025. Background:Randomized trials and observational of patients with cervical artery dissection showed no significant difference in ischemic stroke risk with anticoagulation versus antiplatelet therapy.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
84 
Let's personalize your content